Andrographolide inhibits breast cancer through suppressing COX-2 expression and angiogenesis via inactivation of p300 signaling and VEGF pathway

Andrographolide inhibits breast cancer through suppressing COX-2 expression and angiogenesis via inactivation of p300 signaling and VEGF pathway

Abstract Background Andrographolide (Andro), a diterpenoid lactone, has been used for treatment of various cancers with less adverse effects. However, the underlying mechanisms regarding its anti-tumor mechanism still remain unclear. Methods Cell viability and proliferation were measured by CCK8 and...

Full description

Bibliographic Details
Main Authors: Yulin Peng, Yan Wang, Ning Tang, Dongdong Sun, Yulong Lan, Zhenlong Yu, Xinyu Zhao, Lei Feng, Baojing Zhang, Lingling Jin, Fabiao Yu, Xiaochi Ma, Chuanzhu Lv
Format: Article
Language:English
Published: BMC 2018-10-01
Series:Journal of Experimental & Clinical Cancer Research
Subjects:
Andrographolide
COX-2/NF-κB
Angiogenesis
p300
Breast cancer
Online Access:http://link.springer.com/article/10.1186/s13046-018-0926-9

Internet

http://link.springer.com/article/10.1186/s13046-018-0926-9

Similar Items